|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang YL, Feng SH, Zhu J, Zhu GP, Li DS,
Wang Y, Zhu YX, Sun GH and Ji QH: Impact of lymph node ratio on the
survival of patients with hypopharyngeal squamous cell carcinoma: A
population-based analysis. PLoS One. 8:e566132013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hall SF, Groome PA, Irish J and O'Sullivan
B: The natural history of patients with squamous cell carcinoma of
the hypopharynx. Laryngoscope. 118:1362–1371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boyle P and Ferlay J: Cancer incidence and
mortality in Europe, 2004. Ann Oncol. 16:481–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takes RP, Strojan P, Silver CE, Bradley
PJ, Haigentz M Jr, Wolf GT, Shaha AR, Hartl DM, Olofsson J,
Langendijk JA, et al: Current trends in initial management of
hypopharyngeal cancer: The declining use of open surgery. Head
Neck. 34:270–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fernandes-Alnemri T, Yu JW, Datta P, Wu J
and Alnemri ES: AIM2 activates the inflammasome and cell death in
response to cytoplasmic DNA. Nature. 458:509–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hornung V, Ablasser A, Charrel-Dennis M,
Bauernfeind F, Horvath G, Caffrey DR, Latz E and Fitzgerald KA:
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating
inflammasome with ASC. Nature. 458:514–518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dihlmann S, Tao S, Echterdiek F, Herpel E,
Jansen L, Chang- Claude J, Brenner H, Hoffmeister M and Kloor M:
Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is
closely associated with poor survival in colorectal cancer
patients. Int J Cancer. 135:2387–2396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schulmann K, Brasch FE, Kunstmann E, Engel
C, Pagenstecher C, Vogelsang H, Krüger S, Vogel T, Knaebel HP,
Rüschoff J, et al: HNPCC-associated small bowel cancer: Clinical
and molecular characteristics. Gastroenterology. 128:590–599. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Woerner SM, Kloor M, Schwitalle Y, Youmans
H, Doeberitz Mv, Gebert J and Dihlmann S: The putative tumor
suppressor AIM2 is frequently affected by different genetic
alterations in microsatellite unstable colon cancers. Genes
Chromosomes Cancer. 46:1080–1089. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim TM, Laird PW and Park PJ: The
landscape of microsatellite instability in colorectal and
endometrial cancer genomes. Cell. 155:858–868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen LC, Wang LJ, Tsang NM, Ojcius DM,
Chen CC, Ouyang CN, Hsueh C, Liang Y, Chang KP, Chen CC, et al:
Tumour inflammasome-derived IL-1β recruits neutrophils and improves
local recurrence-free survival in EBV-induced nasopharyngeal
carcinoma. EMBO Mol Med. 4:1276–1293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ponomareva L, Liu H, Duan X, Dickerson E,
Shen H, Panchanathan R and Choubey D: AIM2, an IFN-inducible
cytosolic DNA sensor, in the development of benign prostate
hyperplasia and prostate cancer. Mol Cancer Res. 11:1193–1202.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang LJ, Hsu CW, Chen CC, Liang Y, Chen
LC, Ojcius DM, Tsang NM, Hsueh C, Wu CC and Chang YS:
Interactome-wide analysis identifies end-binding protein 1 as a
crucial component for the speck-like particle formation of
activated absence in melanoma 2 (AIM2) inflammasomes. Mol Cell
Proteomics. 11:1230–1244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kong H, Wang Y, Zeng X, Wang Z, Wang H and
Xie W: Differential expression of inflammasomes in lung cancer cell
lines and tissues. Tumour Biol. 36:7501–7513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kondo Y, Nagai K, Nakahata S, Saito Y,
Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, et
al: Overexpression of the DNA sensor proteins, absent in melanoma 2
and interferon-inducible 16, contributes to tumorigenesis of oral
squamous cell carcinoma with p53 inactivation. Cancer Sci.
103:782–790. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sánchez A, Nagy P and Thorgeirsson SS:
STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur
J Cancer. 39:2093–2098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou T, Chao L, Rong G, Wang C, Ma R and
Wang X: Down-regulation of GRIM-19 is associated with STAT3
overexpression in breast carcinomas. Hum Pathol. 44:1773–1779.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F,
Ha SJ, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of
IL-6R/JAK1/STAT3 signaling induces de novo resistance to
irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abdulghani J, Gu L, Dagvadorj A, Lutz J,
Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T,
et al: Stat3 promotes metastatic progression of prostate cancer. Am
J Pathol. 172:1717–1728. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grandis JR, Drenning SD, Chakraborty A,
Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but
not Stat1 activation for epidermal growth factor receptor-mediated
cell growth in vitro. J Clin Invest. 102:1385–1392. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sahu RP and Srivastava SK: The role of
STAT-3 in the induction of apoptosis in pancreatic cancer cells by
benzyl isothiocyanate. J Natl Cancer Inst. 101:176–193. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo C, Yang G, Khun K, Kong X, Levy D, Lee
P and Melamed J: Activation of Stat3 in renal tumors. Am J Transl
Res. 1:283–290. 2009.PubMed/NCBI
|
|
26
|
Lin TS, Mahajan S and Frank DA: STAT
signaling in the pathogenesis and treatment of leukemias. Oncogene.
19:2496–2504. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Corvinus FM, Orth C, Moriggl R, Tsareva
SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal
K, et al: Persistent STAT3 activation in colon cancer is associated
with enhanced cell proliferation and tumor growth. Neoplasia.
7:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu CL, Jove R and Burakoff SJ:
Constitutive activation of the Janus kinase-STAT pathway in T
lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol.
159:5206–5210. 1997.PubMed/NCBI
|
|
29
|
Niu G, Bowman T, Huang M, Shivers S,
Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H: Roles of
activated Src and Stat3 signaling in melanoma tumor cell growth.
Oncogene. 21:7001–7010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rahaman SO, Harbor PC, Chernova O, Barnett
GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active
Stat3 suppresses proliferation and induces apoptosis in
glioblastoma multiforme cells. Oncogene. 21:8404–8413. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Darnell JE: Validating Stat3 in cancer
therapy. Nat Med. 11:595–596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Masuda M, Suzui M, Yasumatu R, Nakashima
T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
|
33
|
Leeman RJ, Lui VW and Grandis JR: STAT3 as
a therapeutic target in head and neck cancer. Expert Opin Biol
Ther. 6:231–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lai SY and Johnson FM: Defining the role
of the JAK-STAT pathway in head and neck and thoracic malignancies:
Implications for future therapeutic approaches. Drug Resist Updat.
13:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin WW and Karin M: A cytokine-mediated
link between innate immunity, inflammation, and cancer. J Clin
Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Budczies J, Klauschen F, Sinn BV, Győrffy
B, Schmitt WD, Darb-Esfahani S and Denkert C: Cutoff Finder: A
comprehensive and straightforward Web application enabling rapid
biomarker cut-off optimization. PLoS One. 7:e518622012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wilson JE, Petrucelli AS, Chen L,
Koblansky AA, Truax AD, Oyama Y, Rogers AB, Brickey WJ, Wang Y,
Schneider M, et al: Inflammasome-independent role of AIM2 in
suppressing colon tumorigenesis via DNA-PK and Akt. Nat Med.
21:906–913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Man SM, Zhu Q, Zhu L, Liu Z, Karki R,
Malik A, Sharma D, Li L, Malireddi RK, Gurung P, et al: Critical
role for the DNA sensor AIM2 in stem cell proliferation and cancer.
Cell. 162:45–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
AIM2 blocks colon cancer in three ways.
Cancer Discov. 5:899–900. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Patsos G, Germann A, Gebert J and Dihlmann
S: Restoration of absent in melanoma 2 (AIM2) induces G2/M cell
cycle arrest and promotes invasion of colorectal cancer cells. Int
J Cancer. 126:1838–1849. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ratsimandresy RA, Indramohan M,
Dorfleutner A and Stehlik C: The AIM2 inflammasome is a central
regulator of intestinal homeostasis through the IL-18/IL-22/STAT3
pathway. Cell Mol Immunol. 14:127–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
